Simplifying HIV and hepatitis B treatment to maintain control
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests two ways to simplify your HIV and hepatitis B treatment while keeping the viruses controlled. By switching to a simpler combination, the goal is to maintain low viral levels and reduce the number of medicines you take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to have both HIV and hepatitis B (positive HBsAg test twice, more than 6 months apart).
- Your liver stiffness (FibroScan) must be less than 9 kPa, meaning little or no scarring.
- You must be on the same HIV medication triple therapy for at least 12 months, including tenofovir and either lamivudine or emtricitabine.
- Your HIV and hepatitis B viral loads have been undetectable for at least 2 years (with rare minor blips allowed).
- If you are a woman who could become pregnant, you must agree to use effective contraception and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This trial looks at whether a simpler set of HIV medicines works for people with confirmed HIV-1 infection. It may help by making treatment easier to follow, while monitoring health with regular blood tests.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.